Effector function enhanced recombinant antibody composition

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S133100, C435S069600

Reexamination Certificate

active

07994290

ABSTRACT:
The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.

REFERENCES:
patent: 6737056 (2004-05-01), Presta
patent: 2007/0148165 (2007-06-01), Shitara et al.
patent: 2005/070963 (2005-08-01), None
patent: 2006/105338 (2006-05-01), None
patent: WO 2006088494 (2006-08-01), None
Yamane-Ohnuki, et al. Establishment of FUT8 knockout chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnology and Bioengineering, 2004. vol. 87, pp. 614-622.
Schumaker, Calcott, Spiegelberg, and Muller-Eberhard. Ultracentrifuge studies of binding of IgG of different subclasses to the C1q subunit of the first component of complement. Biochemistry, 1976. vol. 15, pp. 5175-5181.
Canfield and Morrison. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. Journal of Experimental Medicine, 1991. vol. 173, pp. 1483-1491.
Tao, Smith, and Morrison. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. Journal of Experimental Medicine, 1993. vol. 178, pp. 661-667.
Thommesen, Michaelsen, Loset, Sandlie, and Brekke. Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation. Molecular Immunology, 2000. vol. 37, pp. 995-1004.
Extended European Search Report, Application No. 08703820.4, dated Jul. 23, 2010.
Rinpei Niwa, “IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from ANS297-linked oliogosaccharides”, Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, vol. 306, No. 102, p. 151-160, dated Nov. 30, 2005.
Esohe Idusogie, “Engineered antibodies with increased activity to recruit complement”, Journal of Immunology, American Association of Immunologists, US, vol. 166 No. 4, pp. 2571-2575, dated Feb. 15, 2001.
Akito Natsume, “Engineered Antibodies of IgG1/IgG3 Mixed Isotype wuth Enhanced Cytotoxic Activities”, Cancer Research, vol. 68, No. 10, pp. 3863-3872, dated May 10, 2008.
International Search Report issued Mar. 18, 2008, in PCT/JP2008/050993.
A. Morgan et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding”, Immunology, 1995, 86:319-324.
Ole H. Brekke et al., “Human IgG3 Can Adopt the Disulfide Bond Pattern Characteristic for IgG1 Without Resembling it in Complement Mediated Cell Lysis”, Molecular Immunology, 1993, 30(16):1419-1425.
E. Van Loghem et al., “Staphylococcal Protein A and Human IgG Subclasses and Allotypes”, Scandinavian Journal of Immunology, 1982, 15:275-278.
Mitsuo Satoh et al., “The oligosaccharide structure of antibody affects its effector function”, Molecular Medicine, 2003, 40(9):1024-1032.
European Patent Office, Office Action issued in corresponding European Patent Application No. 08703820.4 on May 6, 2011 (in the name of Kyowa Hakko Kirin Co., Ltd.).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Effector function enhanced recombinant antibody composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Effector function enhanced recombinant antibody composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Effector function enhanced recombinant antibody composition will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2746747

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.